Latest Conference Coverage

Advances in Therapeutics and Imaging from European Stroke Organization Conference 2025: Kevin Sheth, MD

Looking at the Importance of Family-Centered Care Approaches in Pediatric Sleep Medicine

Funke Afolabi-Brown, MD, FAASM, chief executive officer of Restful Sleep MD, discussed the potential role of family dynamics and individualized planning in the effective management of pediatric sleep disorders.

Emerging Considerations in Peripheral Nerve Injury and Surgical Intervention: Kevin Swong, MD

The neurosurgeon at Northwestern Medicine discussed diagnostic approaches, evolving treatment strategies, and the importance of timely referral in managing peripheral nerve injuries. [WATCH TIME: 3 minutes]

Phase 2 Study to Test Therapeutic Potential of Samelisant for Narcolepsy Type 1

A new phase 2 study explores samelisant's potential to treat cataplexy in narcolepsy type 1, promising improved patient outcomes and safety.

National RLS Registry Provides Long-Term Insights Into Opioid Use for Restless Legs Syndrome

New 5-year findings from the National RLS Opioid Registry presented at SLEEP 2025 highlight the long-term stability and dose trends of low-dose opioid therapy in patients with restless legs syndrome.

Rationale Behind NVG-2089 as New Therapy for CIDP: Pamela Conley; Alan Glicklich, MD

Members from Nuvig Therapeutics discussed how NVG-2089 could improve the CIDP treatment landscape by offering IVIG-like efficacy with a better safety and administration profile. [WATCH TIME: 3 minutes]

Small-Scale Study Highlights Positive Impacts of Once-Nightly Sodium Oxybate on Sleep-Related Eating Disorder

Switching to once-nightly sodium oxybate significantly improves sleep-related eating disorder in narcolepsy patients, enhancing overall treatment outcomes.

Tonic Motor Activation Effective in Treating Both Painful and Painless Restless Legs Syndrome

An interim analysis of an ongoing study suggested that the tonic motor activation demonstrated comparable short-term outcomes for both painful and painless forms of restless legs syndrome.

Supporting Stroke Recovery Through the Glymphatic System: Joyce Lee-Iannotti, MD, FAAN, FAASM

The sleep and stroke neurologist at Barrow Neurological Institute detailed how improving glymphatic function may prevent strokes and enhance recovery from both hemorrhagic and ischemic events. [WATCH TIME: 5 minutes]

Low-Sodium Oxybate Improves Daytime Sleepiness and Sleep Architecture in Phase 4 Narcolepsy Trial

Findings from the Jazz DUET study presented at SLEEP 2025 showed that low-sodium oxybate reduced daytime sleepiness and improved sleep parameters in patients with narcolepsy types 1 and 2.

Exploring the Overlooked Role of Orexin in Alzheimer Disease and Sleep Dysfunction: Lea Grinberg, MD, PhD

The neuropathologist at Mayo Clinic Florida discussed her presentation from SLEEP 2025, outlining how early tau accumulation in wake-promoting brain regions contributes to sleep disturbances before Alzheimer disease symptoms arise. [WATCH TIME: 3 minutes]

NeuroVoices: Andrew Varga, MD, on Debating Whether Brain Cleansing Prevents Alzheimer Disease

The neuroscientist and physician at Mount Sinai explored the role of sleep-dependent brain clearance in Alzheimer disease and how emerging research is challenging longstanding assumptions.

Post-Hoc Analysis Links Tirzepatide Treatment to Reduced Daytime Sleepiness in OSA and Obesity

Data from a pair of phase 3 trials suggest that tirzepatide treatment may improve patient-reported measures of sleepiness in individuals with obstructive sleep apnea and obesity.

Adapting Cognitive Behavioral Therapy for Nightmare Disorder in Children: Lisa Cromer, PhD

The professor of psychology at the University of Tulsa provided insight on how her team adapted CBT for children with nightmares using a learning-theory approach that targets the fear-avoidance cycle. [WATCH TIME: 5 minutes]

Investigational Therapy TAK-861 Reduces Microsleeps in Phase 2 Trial of Narcolepsy Type 1

New phase 2 trial data presented at SLEEP 2025 suggest TAK-861 significantly decreased microsleep frequency and delayed onset of first microsleep in individuals with narcolepsy type 1.

Phase 3 REST-ON Analysis Provides Insights Into Hypnagogic and Hypnopompic Hallucinations of Narcolepsy

New analysis reveals insights on hypnagogic and hypnopompic hallucinations in narcolepsy patients treated with once-nightly sodium oxybate.

Emergence of Precision Pharmacotherapy in Sleep Apnea: Danny Eckert, PhD

The director of sleep health at Flinders University explained how new mechanistic insights are enabling targeted pharmacotherapy and trait-based treatment for obstructive sleep apnea. [WATCH TIME: 3 minutes]

Actigraphy-Based Nap Detection Algorithm Highlights Increased Napping in Narcolepsy Type 1, Reduced Napping With TAK-861

A newly presented actigraphy-based algorithm demonstrated high accuracy in detecting daytime naps, offering insights into napping behavior changes in patients with narcolepsy type 1.

Post-Hoc Analysis Gives Safety Insights on Switch From Twice-Nightly Oxybate to Once-Nightly Treatment

A recent analysis reveals the safety profile of once-nightly sodium oxybate for narcolepsy, highlighting low discontinuation rates and common adverse events.

Study Highlights High Prevalence and Severity of Restless Legs Syndrome in Pregnant Women

A new study presented at SLEEP 2025 reported that more than one-quarter of pregnant women experienced restless legs syndrome, with prior history of the condition emerging as a significant risk factor.

Solriamfetol Shows Therapeutic Benefits on Neuropsychological Outcomes in Excessive Daytime Sleepiness

New research reveals solriamfetol significantly enhances neuropsychological outcomes in patients with obstructive sleep apnea and excessive daytime sleepiness.

Negative Study Findings Further Question Effectiveness of Transcranial Direct Stimulation to Treat Insomnia

Recent research reveals that transcranial direct current stimulation (tDCS) shows no significant benefits for insomnia, highlighting the need for larger studies.

Wearable Devices Preferred Over Traditional Sleep Studies When Monitoring Ambulatory Sleep in Pediatric Lennox-Gastaut Syndrome

A newly presented study at SLEEP 2025 explored the practicality of various methods, such as the Apple Watch and polysomnogram, for assessing sleep in pediatric patients with Lennox-Gastaut syndrome.

REFRESH Study to Test Real-World Clinical Effectiveness of Once-Nightly Sodium Oxybate

A new study evaluates the effectiveness and safety of once-nightly sodium oxybate for narcolepsy, aiming to enhance patient treatment experiences.

Samelisant Significantly Reduces Excessive Daytime Sleepiness in Phase 2 Narcolepsy Study

A phase 2 study shows samelisant significantly reduces excessive daytime sleepiness in narcolepsy, paving the way for further research and development.

Clinical Insight on Challenges and Evolving Strategies in Advanced Multiple Sclerosis Care

Sam Hooshmand, DO, assistant professor of neurology at the Medical College of Wisconsin, discussed the complexities of defining, diagnosing, and managing advanced MS.

Expanding the Scope of Wellness Research in Multiple Sclerosis: Kathy Zackowski, PhD, OTR

The associate vice president of research at the National MS Society discussed a growing research initiative focused on defining and promoting evidence-based psychosocial wellness strategies for individuals with MS. [WATCH TIME: 6 minutes]

Conversations on Biomarker Use in Multiple Sclerosis Remyelination Research

Ahmed Abdelhak, MD, assistant professor of neurology at the UCSF, discussed the evolving landscape of biomarkers in multiple sclerosis and their potential to transform remyelination approaches.

Investigating Treatment Differences of Off-Label and Marketed Therapies for NMOSD: Sumaira Ahmed

The executive director of The Sumaira Foundation discussed a newly funded international trial assessing both approved and off-label NMOSD therapies to better inform treatment decisions and patient care. [WATCH TIME: 2 minutes]

REGENXBIO Reports Positive Phase 1/2 Data for Higher Dose of RGX-202 in Duchenne Muscular Dystrophy